Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam On-Demand Webinar Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam Risdiplam (EVRYSDI) is approved for the treatment of patients with spinal muscular atrophy ≥ 2…Certara2021 年 10 月 7 日
FDA’s Digital Transformation: The Future of Technology and How to Prepare On-Demand Webinar 美国食品药品监督管理局数字转型:技术的未来以及如何准备 As Life-Science manufacturers embrace new technologies to speed time to market and products become more…Certara2021 年 10 月 5 日
Using Real-world Evidence to Advance Market Access for New Therapeutics White Paper 运用真实世界证据推动新疗法市场准入 Certara2021 年 9 月 29 日
The Scary Future of Rare Disease Management On-Demand Webinar 罕见病管理的“可怕”未来 In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…Certara2021 年 9 月 23 日
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers Publication Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often,…Certara2021 年 9 月 23 日
Building a Robust Clinical Pharmacology & Model-Informed Drug Development Strategy for New Alzheimer’s Disease Drugs Blog Building a Robust Clinical Pharmacology & Model-Informed Drug Development Strategy for New Alzheimer’s Disease Drugs Alzheimer's disease (AD) is one of the most common forms of neurodegenerative dementia in the…Certara2021 年 9 月 20 日
Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Case Study Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Certara2021 年 8 月 20 日
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling & Simulation White Paper 使用经临床验证的计算机建模和模拟进行免疫原性预测和剂量优化 Certara2021 年 8 月 19 日